{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:41:03Z","timestamp":1791013263776,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1038\/s41390-021-01728-8","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T21:02:41Z","timestamp":1631134961000},"page":"874-878","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Metabolic control during the neonatal period in phenylketonuria: associations with childhood IQ"],"prefix":"10.1038","volume":"91","author":[{"given":"Geertje B.","family":"Liemburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan C. J.","family":"Huijbregts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhold","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rianne","family":"Jahja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Weglage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Och","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes G. M.","family":"Burgerhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francjan J.","family":"van Spronsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"key":"1728_CR1","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","volume":"376","author":"N Blau","year":"2010","unstructured":"Blau, N., Van Spronsen, F. J. & Levy, H. L. Phenylketonuria. Lancet 376, 1417\u20131427 (2010).","journal-title":"Lancet"},{"key":"1728_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrendo.2010.125","volume":"6","author":"FJ Van Spronsen","year":"2010","unstructured":"Van Spronsen, F. J. Phenylketonuria: a 21st century perspective. Nat. Rev. Endocrinol. 6, 509\u2013514 (2010).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1728_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0022-3476(99)70138-1","volume":"135","author":"S Kure","year":"1999","unstructured":"Kure, S. et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J. Pediatr. 135, 375\u2013378 (1999).","journal-title":"J. Pediatr."},{"key":"1728_CR4","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/j.ymgme.2009.10.016","volume":"99","author":"MJ De Groot","year":"2010","unstructured":"De Groot, M. J., Hoeksma, M., Blau, N., Reijngoud, D. J. & Van Spronsen, F. J. Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses. Mol. Genet. Metab. 99, S86\u2013S89 (2010).","journal-title":"Mol. Genet. Metab."},{"key":"1728_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(13)61841-3","volume":"384","author":"N Longo","year":"2014","unstructured":"Longo, N. et al. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet 384, 37\u201344 (2014).","journal-title":"Lancet"},{"key":"1728_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ymgme.2018.03.003","volume":"124","author":"CO Harding","year":"2018","unstructured":"Harding, C. O. et al. Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial. Mol. Genet. Metab. 124, 20\u201326 (2018).","journal-title":"Mol. Genet. Metab."},{"key":"1728_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ymgme.2017.04.013","volume":"122","author":"M Goldfinger","year":"2017","unstructured":"Goldfinger, M. et al. Partial rescue of neuropathology in the murine model of PKU following administration of recombinant phenylalanine ammonia lyase (pegvaliase). Mol. Genet. Metab. 122, 33\u201335 (2017).","journal-title":"Mol. Genet. Metab."},{"key":"1728_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ymgme.2010.05.017","volume":"101","author":"GM Enns","year":"2010","unstructured":"Enns, G. M. et al. Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence. Mol. Genet. Metab. 101, 99\u2013109 (2010).","journal-title":"Mol. Genet. Metab."},{"key":"1728_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11065-007-9021-2","volume":"17","author":"JJ Moyle","year":"2007","unstructured":"Moyle, J. J., Fox, A. M., Arthur, M., Bynevelt, M. & Burnett, J. R. Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU. Neuropsychol. Rev. 17, 91\u2013101 (2007).","journal-title":"Neuropsychol. Rev."},{"key":"1728_CR10","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.neubiorev.2008.11.001","volume":"33","author":"J Albrecht","year":"2009","unstructured":"Albrecht, J., Garbade, S. F. & Burgard, P. Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: a meta-analysis. Neurosci. Biobehav. Rev. 33, 414\u2013421 (2009).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"1728_CR11","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0149-7634(02)00040-4","volume":"26","author":"SC Huijbregts","year":"2002","unstructured":"Huijbregts, S. C., De Sonneville, L. M., Van Spronsen, F. J., Licht, R. & Sergeant, J. A. The neuropsychological profile of early and continuously treated phenylketonuria: orienting, vigilance, and maintenance versus manipulation-functions of working memory. Neurosci. Biobehav. Rev. 26, 697\u2013712 (2002).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"1728_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ymgme.2007.05.006","volume":"92","author":"SE Waisbren","year":"2007","unstructured":"Waisbren, S. E. et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol. Genet. Metab. 92, 63\u201370 (2007).","journal-title":"Mol. Genet. Metab."},{"key":"1728_CR13","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.ymgme.2013.08.013","volume":"110","author":"J Weglage","year":"2013","unstructured":"Weglage, J. et al. Neurocognitive functioning in adults with phenylketonuria: results of a long term study. Mol. Genet. Metab. 110, S44\u2013S48 (2013).","journal-title":"Mol. Genet. Metab."},{"key":"1728_CR14","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s10519-017-9863-1","volume":"47","author":"R Jahja","year":"2017","unstructured":"Jahja, R. et al. Long-term follow-up of cognition and mental health in adult phenylketonuria: a PKU-COBESO study. Behav. Genet. 47, 486\u2013497 (2017).","journal-title":"Behav. Genet."},{"key":"1728_CR15","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(16)30320-5","volume":"5","author":"FJ Van Spronsen","year":"2017","unstructured":"Van Spronsen, F. J. et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 5, 743\u2013756 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1728_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/gim.2013.157","volume":"16","author":"J Vockley","year":"2014","unstructured":"Vockley, J. et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet. Med. 16, 188\u2013200 (2014).","journal-title":"Genet. Med."},{"key":"1728_CR17","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jpeds.2013.12.015","volume":"164","author":"R Jahja","year":"2014","unstructured":"Jahja, R., Huijbregts, S. C., De Sonneville, L. M., Van der Meere, J. J. & Van Spronsen, F. J. Neurocognitive evidence for revision of treatment targets and guidelines for phenylketonuria. J. Pediatr. 164, 895\u2013899 (2014).","journal-title":"J. Pediatr."},{"key":"1728_CR18","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s10545-011-9329-1","volume":"34","author":"KS Viau","year":"2011","unstructured":"Viau, K. S. et al. Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria. J. Inherit. Metab. Dis. 34, 963\u2013971 (2011).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1728_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0028-3932(01)00078-1","volume":"40","author":"SCJ Huijbregts","year":"2002","unstructured":"Huijbregts, S. C. J. et al. Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations. Neuropsychologia 40, 7\u201315 (2002).","journal-title":"Neuropsychologia"},{"key":"1728_CR20","doi-asserted-by":"publisher","first-page":"20170254","DOI":"10.1098\/rstb.2017.0254","volume":"373","author":"MI Posner","year":"2018","unstructured":"Posner, M. I. & Rothbart, M. K. Temperament and brain networks of attention. Philos. Trans. R. Soc. Lond. B Biol. Sci. 373, 20170254 (2018).","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"1728_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.conb.2010.01.006","volume":"20","author":"LH Somerville","year":"2010","unstructured":"Somerville, L. H. & Casey, B. J. Developmental neurobiology of cognitive control and motivational systems. Curr. Opin. Neurbiol. 20, 236\u2013241 (2010).","journal-title":"Curr. Opin. Neurbiol."},{"key":"1728_CR22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1203\/00006450-199703000-00011","volume":"41","author":"P Burgard","year":"1997","unstructured":"Burgard, P., Rey, F., Rupp, A., Abadie, V. & Rey, J. Neuropsychologic functions of early treated patients with phenylketonuria, on and off diet: results of a cross-national and cross-sectional study. Pediatr. Res. 41, 368\u2013374 (1997).","journal-title":"Pediatr. Res."},{"key":"1728_CR23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1651-2227.1994.tb13455.x","volume":"407","author":"LW Van der Schot","year":"1994","unstructured":"Van der Schot, L. W., Doesburg, W. H. & Sengers, R. C. The phenylalanine response curve in relation to growth and mental development in the first year of life. Acta Paediatr. 407, 68\u201369 (1994).","journal-title":"Acta Paediatr."},{"key":"1728_CR24","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1136\/adc.65.5.472","volume":"65","author":"I Smith","year":"1990","unstructured":"Smith, I., Beasley, M. G. & Ades, A. E. Intelligence and quality of dietary treatment in phenylketonuria. Arch. Dis. Child. 65, 472\u2013478 (1990).","journal-title":"Arch. Dis. Child."},{"key":"1728_CR25","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.ymgme.2013.10.011","volume":"110","author":"R Jahja","year":"2013","unstructured":"Jahja, R. et al. Mental health and social functioning in early treated phenylketonuria: the PKU-COBESO study. Mol. Genet. Metab. 110, S57\u2013S61 (2013).","journal-title":"Mol. Genet. Metab."},{"key":"1728_CR26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10545-005-0445-7","volume":"28","author":"R Feldmann","year":"2005","unstructured":"Feldmann, R., Denecke, J., Grenzebach, M. & Weglage, J. Frontal lobe-dependent functions in treated phenylketonuria: blood phenylalanine concentrations and long-term deficits in adolescents and young adults. J. Inherit. Metab. Dis. 28, 445\u2013455 (2005).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1728_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1023\/A:1005664231017","volume":"23","author":"J Weglage","year":"2000","unstructured":"Weglage, J. et al. Behavioural and emotional problems in early-treated adolescents with phenylketonuria in comparison with diabetic patients and healthy controls. J. Inherit. Metab. Dis. 23, 487\u2013496 (2000).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1728_CR28","unstructured":"Kort, W. et al. Wechsler Intelligence Scale for Children-III-NL (Pearson Clinical and Talent Assessment, 2005)."},{"key":"1728_CR29","unstructured":"Petermann, F. F. & Petermann, U. (eds.) HAWIK-IV 3rd edn (Huber, 2010)."},{"key":"1728_CR30","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1542\/peds.72.3.390","volume":"72","author":"ER McCabe","year":"1983","unstructured":"McCabe, E. R., McCabe, L., Mosher, G. A., Allen, R. J. & Berman, J. L. Newborn screening for phenylketonuria: predictive validity as a function of age. Pediatrics 72, 390\u2013398 (1983).","journal-title":"Pediatrics"},{"key":"1728_CR31","unstructured":"RStudio. RStudio: integrated development environment for R (version 1.1.453). http:\/\/www.rstudio.org (2012)."},{"key":"1728_CR32","unstructured":"Eid, M., Gollwitzer, M. & Schmitt, M. Statistik und Forschungsmethoden Lehrbuch (Beltz, 2011)."},{"key":"1728_CR33","unstructured":"Lenhard, W. & Lenhard, A. Hypothesis Tests for Comparing Correlations (Psychometrica, 2014)."},{"key":"1728_CR34","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.ymgme.2009.10.007","volume":"99","author":"SE Christ","year":"2010","unstructured":"Christ, S. E., Huijbregts, S. C., De Sonneville, L. M. & White, D. A. Executive function in early-treated phenylketonuria: profile and underlying mechanisms. Mol. Genet. Metab. 99, S22\u2013S32 (2010).","journal-title":"Mol. Genet. Metab."},{"key":"1728_CR35","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.ymgme.2013.10.001","volume":"110","author":"SC Huijbregts","year":"2013","unstructured":"Huijbregts, S. C., Gassio, R. & Campistol, J. Executive functioning in context: Relevance for treatment and monitoring of phenylketonuria. Mol. Genet. Metab. 110, S25\u2013S30 (2013).","journal-title":"Mol. Genet. Metab."},{"key":"1728_CR36","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1080\/87565640802101482","volume":"33","author":"K DeRoche","year":"2008","unstructured":"DeRoche, K. & Welsh, M. Twenty-five years of research on neurocognitive outcomes in early-treated phenylketonuria: intelligence and executive function. Dev. Neuropsychol. 33, 474\u2013504 (2008).","journal-title":"Dev. Neuropsychol."},{"key":"1728_CR37","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ymgme.2013.09.001","volume":"110","author":"M Cleary","year":"2013","unstructured":"Cleary, M. et al. Fluctuations in phenylalanine concentrations in phenylketonuria: A review of possible relationships with outcomes. Mol. Genet. Metab. 110, 418\u2013423 (2013).","journal-title":"Mol. Genet. Metab."},{"key":"1728_CR38","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1007\/PL00014251","volume":"155","author":"J Zeman","year":"1996","unstructured":"Zeman, J. et al. Intellectual and school performance in adolescents with phenylketonuria according to their dietary compliance. The Czech-Slovak Collaborative Study. Eur. J. Pediatr. 155, S56\u2013S58 (1996).","journal-title":"Eur. J. Pediatr."},{"key":"1728_CR39","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.ymgme.2011.07.015","volume":"104","author":"MJ Gonzalez","year":"2011","unstructured":"Gonzalez, M. J. et al. Neurological complications and behavioral problems in patients with phenylketonuria in a Follow-up Unit. Mol. Genet. Metab. 104, S73\u2013S79 (2011).","journal-title":"Mol. Genet. Metab."},{"key":"1728_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/8904_2014_358","volume":"18","author":"D Van Vliet","year":"2015","unstructured":"Van Vliet, D. et al. Infants with Tyrosinemia Type 1: should phenylalanine be supplemented? JIMD Rep. 18, 117\u2013124 (2015).","journal-title":"JIMD Rep."},{"key":"1728_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1259-2","volume":"14","author":"K Van Vliet","year":"2019","unstructured":"Van Vliet, K. et al. Emotional and behavioral problems, quality of life and metabolic control in NTBC-treated Tyrosinemia type 1 patients. Orphanet J. Rare Dis. 14, 285 (2019).","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-021-01728-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-021-01728-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-021-01728-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T13:25:45Z","timestamp":1651584345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-021-01728-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1728"],"URL":"https:\/\/doi.org\/10.1038\/s41390-021-01728-8","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,8]]},"assertion":[{"value":"26 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.C.J.H. has participated in strategic advisory boards and received grants and honoraria as a consultant and\/or speaker from Biomarin, Merck- Serono, Homology Medicines, and Nutricia. R.J. has received honoraria as a speaker and consultant from Merck- Serono and Biomarin. F.J.v.S. has received research grants, advisory board fees, and speaker\u2019s honoraria from Nutricia Research, Merck-Serono, Biomarin, Codexis, Alexion, Vitaflo, MendeliKABS, Promethera, SOBI, APR, and ARLA Foods Int. G.B.L., F.R., R.F., J.W., U.O. and J.G.M.B. declared that they do not have potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Participants and\/or parents gave written informed consent to participate in the study and for using their data in this report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}